Kenvue’s stock tumbled when U.S. President Donald Trump, with Health & Human Services Secretary Robert F. Kennedy, Jr., standing behind him, declared that its product, Tylenol, leads to autism in children when taken by mothers during pregnancy. As social channels were flooded with misinformation supporting the evidenceless claim, it’s easy to imagine the stock continuing to slide, mirroring the trajectory launched by attacks on Bud Light. Remarkably, the stock recovered after one day, thanks largely to Tylenol’s savvy and almost perfect response to the crisis. Tylenol isn’t the first brand to find itself in President Trump’s crosshairs. It is unlikely to be the last. In this short, midweek episode, Neville and Shel explore what the company got right, and what other companies can do to prepare for their turn in the glare of the presidential spotlight. Links from this episode: The US President Called Your Product Dangerous. What Do You Do Now? – Darden Report Online How Companies Can Respond To Allegations Their Products Are Dangerous Tylenol says old post ‘taken of out context’ by White House  Tylenol maker responds to Trump’s acetaminophen claims Tylenol is Just the Latest Brand Trump Has Picked a Fight With Tylenol’s Maker Shows How to Respond to Crisis Tylenol maker shares rebound a day after Trump’s unfounded claims about its safety Lawsuits against Tylenol’s maker get a boost after Trump’s comments Tylenol Issues Clarification After White House Resurfaces 2017 Tweet on Usage During Pregnancy